11 March 2019[1]
EMA/PRAC/97587/2019
Pharmacovigilance Risk Assessment Committee (PRAC)

PRAC recommendations on signals

Adopted at the 11-14 February 2019 PRAC meeting

This document provides an overview of the recommendations adopted by the Pharmacovigilance Risk Assessment Committee (PRAC) on the signals discussed during the meeting of 11-14 February 2019 (including the signal European Pharmacovigilance Issues Tracking Tool [EPITT][2] reference numbers).

PRAC recommendations to provide supplementary information are directly actionable by the concerned marketing authorisation holders (MAHs). PRAC recommendations for regulatory action (e.g. amendment of the product information) are submitted to the Committee for Medicinal Products for Human Use (CHMP) for endorsement when the signal concerns Centrally Authorised Products (CAPs), and to the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) for information in the case of Nationally Authorised Products (NAPs). Thereafter, MAHs are expected to take action according to the PRAC recommendations.

When appropriate, the PRAC may also recommend the conduct of additional analyses by the Agency or Member States.

MAHs are reminded that in line with Article 16(3) of Regulation No (EU) 726/2004 and Article 23(3) of Directive 2001/83/EC, they shall ensure that their product information is kept up to date with the current scientific knowledge including the conclusions of the assessment and recommendations published on the European Medicines Agency (EMA) website (currently acting as the EU medicines webportal).

For CAPs, at the time of publication, PRAC recommendations for update of product information have been agreed by the CHMP at their plenary meeting (25-28 February 2019) and corresponding variations will be assessed by the CHMP.

For nationally authorised medicinal products, it is the responsibility of the National Competent Authorities (NCAs) of the Member States to oversee that PRAC recommendations on signals are adhered to.

Variations for CAPs are handled according to established EMA procedures. MAHs are referred to the available guidance. Variations for NAPs (including via mutual recognition and decentralised procedures) are handled at national level in accordance with the provisions of the Member States.

[1] Intended publication date. The actual publication date can be checked on the webpage dedicated to PRAC recommendations on safety signals.
[2] The relevant EPITT reference number should be used in any communication related to a signal.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

The timeline recommended by PRAC for submission of variations following signal assessment is applicable to both innovator and generic medicinal products, unless otherwise specified.

For procedural aspects related to the handling of PRAC recommendations on signals (e.g. submission requirements, contact points, etc.) please refer to the Questions and Answers on signal management.

1. Recommendations for update of the product information[3]

None.

2. Recommendations for submission of supplementary information

INN	Signal (EPITT No)	PRAC Rapporteur	Action for MAH	MAH
Armodafinil; modafinil	Evaluation of data on foetal outcomes including congenital anomalies from a single observational study in the US (19367)	Martin Huber (DE)	Supplementary information requested (submission by 8 March 2019)	Teva
Bevacizumab	Splenic infarction (19344)	Doris Irene Stenver (DK)	Assess in the next PSUR (submission by 6 May 2019)	Roche Registration GmbH
Olanzapine	Salivary hypersecretion (19357)	Kimmo Jaakkola (FI)	Assess in the next PSUR (submission by 29 June 2019)	Eli Lilly Nederland B.V.
Propylthiouracil	Risk of congenital anomalies	Martin Huber (DE)	Supplementary information requested (submission by 11 April 2019)	Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories, RPH Pharmaceuticals, Takeda, Admeda Arzneimittel
Secukinumab	Dermatitis exfoliative generalised (19354)	Eva Segovia (ES)	Supplementary information requested (submission by 11 April 2019)	Novartis Europharm Ltd
Sulfasalazine	Interference with dihydronicotinamide-adenine dinucleotide / dihydronicotinamide-adenine dinucleotide phosphate (NADH/NADP) reaction assays (19351)	Anette Kirstine Stark (DK)	Supplementary information requested (submission by 11 April 2019)	Pfizer

[3] Translations in all official EU languages of the new product information adopted by PRAC are also available to MAHs on the EMA website.

INN	Signal (EPITT No)	PRAC Rapporteur	Action for MAH	MAH
Tocilizumab	Facial paralysis (19295)	Brigitte Keller-Stanislawski (DE)	Supplementary information requested (submission by 5 April 2019)	Roche Registration GmbH

3. Other recommendations

INN	Signal (EPITT No)	PRAC Rapporteur	Action for MAH	MAH
Angiotensin converting enzyme (ACE) inhibitors: benazepril, captopril, cilazapril, delapril, enalapril, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, zofenopril	Evaluation of data on risk of lung cancer from a population based cohort study (19346)	Ronan Grimes (IE)	Routine pharmacovigilance	MAHs of ACE inhibitors containing medicinal products
Olanzapine	Gestational diabetes (19306)	Kimmo Jaakkola (FI)	Routine pharmacovigilance	MAHs of olanzapine-containing products